CYBERNA builds a blood-based diagnostic platform for ultra-early cancer detection, shifting oncology upstream before tumors form by leveraging epitranscriptomic signatures that capture early cellular changes. We operate a biotech-inspired model, developing patented, transferable diagnostic assets licensed to IVD companies and CLIA labs.
